Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang, Jianming Xu, Yun Chen, Wu Zhuang, Yiping Zhang, Zhendong Chen, Jia Chen, Helong Zhang, Zuoxing Niu, Qingxia Fan, Lizhu Lin, Kangsheng Gu, Ying Liu, Yi Ba, Zhanhui Miao, Xiaodong Jiang, Ming Zeng, Jianhua Chen, Zhichao Fu, Lu Gan, Jun Wang, Xianbao Zhan, Tianshu Liu, Zhiping Li, Lin Shen, Yongqian Shu, Tao Zhang, Qing Yang, Jianjun Zou, Suxia Luo, Feng Peng, Gang Wu, Nong Xu, Lin Zhao, Dong Ma, Shukui Qin, Wei Ren, Enxiao Li, Hongda Lu, Yueyin Pan, Jianping Xiong, Ying Yuan, Yuxian Bai, Lei Chen, Yi Hu, Li Zhang, Yong Gao
The Lancet Oncology, 2020
Abstract
An abstract is not available for this record. Please visit the publisher website for more details.